Revvity, Inc. (RVTY) Covered Calls

Revvity, Inc. is a global health science company providing technologies and services for drug discovery, development, and clinical diagnostics. Formed from the rebranding of PerkinElmer in 2023, the company operates through Life Sciences and Diagnostics segments. It offers a diverse portfolio of reagents, imaging systems, and informatics software to pharmaceutical and biotech firms, diagnostic labs, and academic institutions to accelerate research and improve patient outcomes.

You can sell covered calls on Revvity, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for RVTY (prices last updated Thu 4:16 PM ET):

Revvity, Inc. (RVTY) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
95.57 -5.53 95.65 99.51 2.1M 51 12
Covered Calls For Revvity, Inc. (RVTY)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 95 1.70 97.81 -2.9% -117.6%
Mar 20 95 4.20 95.31 -0.3% -3.0%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

Revvity, Inc. (RVTY) is a specialized health sciences innovator created through the strategic transformation of the legacy PerkinElmer business. Positioned as a pure-play provider of end-to-end solutions, the company spans the entire healthcare continuum from early-stage "discovery to cure." Its business model emphasizes high-margin consumables and software, leveraging deep expertise in genomics, proteomics, and cellular analysis to solve the world’s most challenging health problems.

Core Business and Products

  1. Life Sciences: This segment provides the essential "reagents and tools" for the biopharmaceutical industry. Its portfolio includes the Signals One informatics platform, high-content screening systems like the Opera Phenix OptIQ, and the BioLegend line of premium antibodies. In 2026, the company launched its "Signals Xynthetica" AI-augmented design platform to bridge the gap between in-silico drug design and real-world wet-lab results.
  2. Diagnostics: Revvity is a global leader in immunodiagnostics and reproductive health. It provides critical screening systems for newborn metabolic disorders and prenatal genetic testing. The segment also features the EUROIMMUN brand, which specializes in autoimmune and infectious disease testing, serving clinical laboratories and hospitals worldwide.
  3. Software & Informatics: A high-growth pillar that provides scientific data management and collaboration tools. The 2026 acquisition of ACD/Labs significantly expanded its capabilities in chemical and analytical data orchestration, allowing researchers to harmonize disparate datasets into AI-ready formats.

Competitive Landscape

The life sciences and diagnostic sectors are defined by intense innovation cycles and consolidated market leaders. Revvity’s primary rivals in the broad laboratory and research space are Danaher and Thermo Fisher Scientific. For specialized analytical and diagnostic instrumentation, it competes with Agilent Technologies and Bruker. In the clinical diagnostics market, the company faces competition from Abbott Laboratories and Agilent. Additionally, its high-growth software business increasingly contends with platforms from Google and other specialized informatics providers focused on AI-driven drug discovery.

Strategic Outlook and Innovation

In 2026, the company is executing its "Predictive Discovery" roadmap, headlined by a landmark collaboration with Eli Lilly to provide access to high-quality AI drug discovery models through a federated learning framework. This initiative, called "Signals Xynthetica MaaS" (Models-as-a-Service), allows smaller biotechs to utilize enterprise-grade predictive modeling while keeping their proprietary data secure. Innovation effort is also heavily focused on "Translational Multi-omics," where Revvity’s workflows integrate genomic, proteomic, and imaging data to provide a unified view of disease progression. Management is currently focused on optimizing its footprint following the completion of multi-year cost-efficiency initiatives in early 2026, aiming for sustained operating margin expansion toward 28%. By prioritizing recurring revenue from software and consumables over low-margin instrumentation, the company intends to drive long-term earnings growth even in periods of fluctuating academic and government research funding.